Novavax Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 29, 2021 / 12:40PM GMT
Charles Cliff Duncan - Cantor Fitzgerald & Co., Research Division - Senior Analyst

Hello. Good morning, and welcome to the Cantor Global Healthcare Conference for 2021. My name is Charles Duncan. I'm a Managing Director and Senior Biotechnology Analyst with the firm's equity research department.

And today is day 3 of the annual conference. And I have to say, wow, what a year it has been since we've last hosted our clients in the fall of 2020.

So it's a pleasure to introduce the next presenting company that is Novavax. And with me today, I have Greg Glenn, the Chief Guru or Vaccine Guru, actually the Vice President of R&D. Greg, good morning. Good to see you.

Gregory M. Glenn - Novavax, Inc. - President of Research & Development

Good morning, Charles.

Charles Cliff Duncan - Cantor Fitzgerald & Co., Research Division - Senior Analyst

And I also have John Trizzino, the company's Chief Commercial Officer, who actually used to be the Chief Financial Officer as well. John, nice to see you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot